drugset / Trial / NCT06412588

Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.

NCT06412588

RandomizedParallel-groupOpen-labelTreatment

Summary

It is planned to select Hp infection patients in a number of tertiary hospitals in Jiangsu and randomly divide them into three groups: group A is the classic group, receiving Vonoprazan 20mg, bid + amoxicillin 1.0g, bid + doxycycline 0.1g, bid + colloidal pectin bismuth 0.3g, bid and group C are double groups, respectively, receiving standard dose amoxicillin (1.0 g, bid) combined with vonorrasan dual regimen and doxycycline (0.1g, bid) combined with Vonoprazan dual regimen, the treatment course of the three groups was 14 days, and the oral dose of Vonoprazan was 20mg, bid, the eradication rate, adverse reactions, compliance and other aspects of the three groups were compared, In order to obtain a safe, efficient, economical and convenient Hp eradication program with a wider range of applications.

Timeline

Start
2024-06-15
Primary completion
2026-01-01
Completion
2026-01-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicillin Other / unclassified 1 g Oral
Comparator Bismuth Potassium Citrate Unknown 0.3 g Oral
Comparator Doxycycline Small molecule 0.1 g Oral
Comparator Vonoprazan Other / unclassified 20 mg Oral